About Us

Sinopharm Group Wichita Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Shanghai Modern Pharmaceutical Co., Ltd., a subsidiary of China Pharmaceutical Group. It is a comprehensive pharmaceutical enterprise based on biological fermentation, enzyme catalysis and green synthesis, and has four production technology platforms: biological fermentation pharmaceutical engineering technology, industrial enzyme research and application technology, chemical pharmaceutical engineering technology and analysis and detection technology. With strong technical strength and complete professional supporting facilities, the company has realized the industrial layout of the whole industrial chain from starting raw materials, key intermediates to finished drugs, and is the largest industrial enterprise in the anti-infection section of chemical pharmacy of China Pharmaceutical Group. The company covers a total area of 1325 mu and employs more than 3500 people. In May, 2022, the company was awarded by the provincial people's government as the "chain owner" enterprise of modern pharmaceutical industry chain, a key industrial chain in Shanxi Province.

The company has two production bases in Datong, which are located in pharmaceutical industrial park and high-tech industrial park of Shanxi Datong Economic and Technological Development Zone, with 26 production workshops and 31 production lines. All pharmaceutical production workshops have passed the CGMP certification of China, and the main product production lines have passed the FDA certification or CEP certification of the European Union. It has formed an annual production capacity of 9,000 tons of 6-APA, 9,000 tons of amoxicillin, 1,600 tons of 7-ACA, 600 tons of potassium clavulanate, 1,500 tons of crude cephalosporin, 600 tons of cephalosporin sterile bulk drug, 500 tons of penicillin sterile bulk drug, 200 million powder injections and 4 billion tablets/bag of oral solid preparation.

The company has established a perfect marketing system, forming a domestic and international two-wheel drive development market structure. Products are sold in more than 100 countries and regions around the world. The annual output of the company's core products 6-APA, amoxicillin and ampicillin is close to 18,000 tons. The export of 6-APA ranks the top three in the world, and the output of 7-ACA ranks the second in China. In particular, the series of potassium clavulanate, the leading product, has a domestic market share of 50% and an international market share of 35%.
The company has an independent R&D technology center, perfect R&D facilities and a high-quality professional technical team, forming the R&D capability of the whole industry chain from new products and new processes to industrial applications, and from raw materials to finished drugs. It has successively undertaken major scientific research projects such as major national special science and technology projects and new product fund projects of Sinopharm Group, and won scientific and technological progress awards of the state, provinces, municipalities and Sinopharm Group for many times. In January 2022, the Technology Center won the title of "National Enterprise Technology Center". In July of the same year, he was awarded the title of "Shanxi Technological Innovation Demonstration Enterprise in 2022" by Shanxi Provincial Department of Industry and Information Technology. In April 2023, three products and four specifications of amoxicillin sodium and clavulanate potassium (0.6g, 1.2g), amoxicillin capsule (0.25g) and ceftriaxone sodium for injection (1.0g) successfully passed the conformity evaluation of generic drugs.
Taking social responsibility bravely, the company always adheres to the quality management concept of "quality first, customer first", aims at producing high-quality products, and establishes a quality control system covering the whole process of production operation and customer service, so as to effectively ensure the intrinsic safety of drug quality.

The company always adheres to the safety management concept of "safety first, employees first", strictly implements the main responsibility of safety production, continuously strengthens the construction of safety standardization system, and creates a safe and stable production environment.
The company has always adhered to the business philosophy of giving priority to environmental protection and green development, vigorously promoted energy conservation, emission reduction and recycling, and constantly improved the construction of environmental protection governance system. In 2020, it was awarded the title of "Green Factory" by the Ministry of Industry and Information Technology, and in 2022, it was awarded the "Spring Festival Blue" meritorious enterprise in Datong City.
During the "Tenth Five-Year Plan" period, Sinopharm Wichita will aim at promoting high-quality development, give full play to its comparative advantages in raw materials, coal, electricity